Teva Pharmaceutical Industries Ltd (TEVA)

[EZ2]

Q1 on 5/10 ~~~~~~~~~

Press Release Source: Teva Pharmaceutical Industries Ltd.

Teva to Report First Quarter 2006 Financial Results on May 10, 2006
Wednesday April 26, 12:16 pm ET
Conference Call Scheduled for 8:30 AM ET


JERUSALEM--(BUSINESS WIRE)--April 26, 2006--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) announced today that it will release its first quarter 2006 financial results on Wednesday, May 10, 2006, early in the morning (ET). The earnings release will be available on Teva's web site at www.tevapharm.com.
Teva will host a conference call and live webcast on that same day, at 08:30AM ET to discuss its first quarter 2006 results and overall business environment. A Question & Answer session will follow this discussion.

Investors and other interested parties may access a live webcast through Teva's web site at www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site. Alternatively, a replay of the call can be accessed until May 17, 2006 at midnight (ET), by calling 1-[phone] outside the U.S. or 1-[phone] in the U.S. The Pass Code to access the replay is: Account #: 3055 and Conference ID#: 201219.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities, environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.



Contact:
Teva Investor Relations
Liraz Kalif, (011) 972-3-926-7281
or
Kevin Mannix, 215-591-8912

--------------------------------------------------------------------------------
Source: Teva Pharmaceutical Industries Ltd.